Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs
Ono T et al. Blood Adv, June 2026 (epub ahead of print)
Link to full abstractOno T et al. Blood Adv, June 2026 (epub ahead of print)
Link to full abstract